The ability to mount an effective immune response declines with age, leaving the elderly
increasingly susceptible to infectious diseases and cancer. Rapamycin, an FDA approved drug
to prevent transplant rejection, increases the lifespan and healthspan of mice and
ameliorates age-related declines in immune responsiveness, cancer survival, and cognition in
laboratory animals. Investigators are conducting a translational trial to test whether
rapamycin also improves life functions in humans focusing on elderly persons (aged 70-95).